PLRX: Pliant Therapeutics, Inc.
About
Pliant Therapeutics, Inc. engages in the discovery and development of therapies for fibrotic diseases. It offers product discovery engine. The company is pursuing drug development programs for a range of fibrotic diseases, focusing on tissue-specific integrin modulation and TGF-ß1 signaling inhibition. The company was founded by Bradley Backes, Bill De Grado, Hal Chapman, and Dean Sheppard in June 2015 and is headquartered in South San Francisco, CA.
Current Value
$15.471 Year Return
Current Value
$15.471 Year Return
Key Details
Market Cap
$943.84M
P/E Ratio
-4.64
1Y Stock Return
7.48%
1Y Revenue Growth
-100.00%
Dividend Yield
0.00%
Price to Book
2.7
Strategies that include PLRX
Stock's related to PLRX
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NTLA | 51.82% | $1.60B | -49.08% | 0.00% |
| BEAM | 49.94% | $2.34B | -4.28% | 0.00% |
| OPEN | 49.46% | $1.52B | -37.54% | 0.00% |
| RCKT | 49.30% | $1.31B | -41.78% | 0.00% |
| CRSP | 47.45% | $4.71B | -22.88% | 0.00% |
| IDYA | 46.52% | $2.37B | -15.30% | 0.00% |
| PGEN | 46.24% | $266.19M | -25.50% | 0.00% |
| NVCR | 46.23% | $3.23B | +129.79% | 0.00% |
| CNDT | 46.10% | $661.94M | +29.78% | 0.00% |
| RXRX | 45.75% | $2.95B | +2.29% | 0.00% |
| ALLO | 45.55% | $534.66M | -0.39% | 0.00% |
| MBWM | 44.35% | $818.39M | +36.81% | 2.09% |
| RCUS | 43.20% | $1.46B | -0.99% | 0.00% |
| DNLI | 43.19% | $3.69B | +36.55% | 0.00% |
| AVXL | 43.09% | $790.29M | +13.66% | 0.00% |
| GCO | 43.05% | $398.71M | +9.05% | 0.00% |
| ATRO | 42.99% | $584.30M | +5.21% | 0.00% |
| ACLX | 42.71% | $5.18B | +73.44% | 0.00% |
| DMRC | 42.48% | $739.44M | +2.07% | 0.00% |
| SDGR | 42.42% | $1.64B | -30.32% | 0.00% |
ETF's related to PLRX
News
Yahoo
SOUTH SAN FRANCISCO, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced participation in the following December investor events. Evercore 7th Annual HealthCONx Conference Members of Pliant’s senior management will meet with investors on Tuesday, December 3, 2024.Citi 2024 Global Healthcare Conference Memb
Yahoo
INTEGRIS-PSC featured in an oral late breaker presentation SOUTH SAN FRANCISCO, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the presentation of clinical data at The Liver Meeting® 2024 of the American Association for the Study of Liver Diseases (AASLD) being held in San Diego, California. Bexotegrast,
Yahoo
BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. “A highlight to this quarter’s progress wa
Yahoo
SOUTH SAN FRANCISCO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), today announced that Keith Cummings, M.D., Chief Financial Officer, and Greg Cosgrove, M.D. FCCP, will participate in a fireside chat at the Stifel 2024 Healthcare Conference on Tuesday, November 19, 2024, at 8:35 a.m. Eastern Time at the Lotte New York Palace Hotel in New York, New York. Interested parties may access the live webcast of the fireside chat by visiting the Investor Relations’ Events &
Yahoo
INTEGRIS-PSC to be featured in an oral presentation on Monday, November 18 SOUTH SAN FRANCISCO, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced a late-breaking presentation of results from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) at The Liver Meet
Yahoo
On September 24, 2024, Paradigm Biocapital Advisors LP (Trades, Portfolio) marked a significant portfolio addition by acquiring 3,059,411 shares of Pliant Therapeutics Inc (NASDAQ:PLRX), a notable player in the biopharmaceutical industry. This transaction, executed at a price of $11.33 per share, represents a new holding for the firm, emphasizing its strategic investment in the healthcare sector. The acquisition not only diversifies Paradigm Biocapital's portfolio but also underscores its commitment to investing in companies with groundbreaking medical therapies.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.